EMERYVILLE, Calif.--()--Bionovo, Inc. (NASDAQ: BNVI) today announced that Mary Tagliaferri, M.D., president and chief medical officer of Bionovo, will present a company update at the BIO CEO and Investor Conference in New York, NY on Tuesday, February 12, 2008 at 1:30 p.m. ET.
Topics to be covered will include:
- BZL101 Phase 2 trial in breast cancer
- Gearing up for MF101 Phase 3 in menopausal hot flashes.
- Update on VG101 Phase 1/2 trial for vaginal atrophy.
Interested parties may access a live audio webcast of the presentation via the investor section of the Bionovo website, www.bionovo.com. A replay of the presentation will be archived on the site for up to 3 months after the event.
About Bionovo
Bionovo is a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, markets with significant unmet needs and billions in potential annual revenue. The company applies its expertise in the biology of menopause and cancer to design new drugs derived from botanical sources which have novel mechanisms of action. Based on the results of early and mid-stage clinical trials, Bionovo believes they have discovered new classes of drug candidates within their rich pipeline with the potential to be leaders in their markets. Bionovo is headquartered in Emeryville, California and is traded on the NASDAQ Capital Market under the symbol, "BNVI". For more information about Bionovo and its programs, visit: http://www.bionovo.com.
Facebook
Twitter
LinkedIn
Delicious
Reddit
StumbleUpon
Digg
MySpace
Newsvine
Google Bookmark
Yahoo! Bookmark
Email
Email 
